Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$15.85 USD
-0.19 (-1.18%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $15.95 +0.10 (0.63%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.85 USD
-0.19 (-1.18%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $15.95 +0.10 (0.63%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $14.60, denoting a +0.34% change from the preceding trading day.
What Makes Hims & Hers Health, Inc. (HIMS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
by Zacks Equity Research
Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.
Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Predict a 70.23% Upside in Hims & Hers Health, Inc. (HIMS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 70.2% upside potential for Hims & Hers Health, Inc. (HIMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -33.33% and 3.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 50% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 20% and 5.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 19.61% and 9.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Talkspace, Inc. (TALK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 50% and 7.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
How to Find the Best Cheap Stocks Under $10 to Buy in July
by Benjamin Rains
Today we dive into a pocket of the stock market that many investors like to own as part of diversified portfolios: cheap stocks trading for $10 a share or less. Along with the cheap price tag, the stocks we explore today boast high Zacks Ranks given their improving earnings outlooks.
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYX
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYX
Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Hims & Hers Health, Inc. (HIMS) and Apollo Medical Holdings, Inc. (AMEH) have performed compared to their sector so far this year.
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 16.67% and 6.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -15.79% and 4.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Surges 10.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Hims & Hers Health, Inc. (HIMS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 28.57% and 4.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 33% Upside in Hims & Hers Health, Inc. (HIMS): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Hims & Hers Health, Inc. (HIMS) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 18.18% and 11.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Hims & Hers Health, Inc. (HIMS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health, Inc. (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.